The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 30
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4 · doi:10.1002/1097-0142(20011115)92:10<2592::aid-cncr1612>3.0.co;2-4
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
“A number of nanocarrier-based products have been approved for the treatment of various tumors, and many others are in different phases of clinical trials.(4) In the current review, we first discussed features of different types of nanocarriers (organic, inorganic and hybrid) along with their relevance in cancer therap…”
BackgroundInfluentialLiposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
“Liposomes are spherical lipid vesicles (usually 50–500 nm in diameter particle size) composed of one or more lipid bilayers, as a result of emulsifying natural or synthetic lipids in an aqueous medium [12, 13] (Figure 1).”
BackgroundNanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
“020 intended target and are sequestered by the liver and spleen (if N6 nm) or eliminated though the kidney (if b6 nm) after administration into the body [2,4].”
BackgroundMethodSelf-citationChallenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Gold Nanomaterials at Work in Biomedicine
Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162
Self-citation
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered Nanoparticles for Drug Delivery in Cancer Therapy. https://app.cochat.ai/papers/10.1002/anie.201403036
- The paper
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014). Engineered Nanoparticles for Drug Delivery in Cancer Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.201403036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.